It does have medical benefits. It is the addiction and health hazards from smoking it that are a problem.
This has been known for what seems to me forever
From Duke university
Suggested lead:There is growing evidence that nicotine might actually benefit some people as long as it isn't delivered by smoking. Tom Britt has more.
The recent decision by the Food and Drug Administration to label cigarettes a nicotine delivery system has drawn cheers from many in the scientific community, including Colleen McBride, director of the cancer prevention, detection and control program at Duke University Medical Center. McBride says there is a growing body of evidence that nicotine actually relieves some symptoms of Parkinson's and Alzheimer's disease, and appears to help those with severe depression focus.
"And in fact we might put some of these people on nicotine patches or some type of nicotine replacement therapy for life, because the nicotine itself is not the bad guy - it's the mode of administration."
McBride says there is ongoing research into possible uses of nicotine in a variety of disease treatment programs. However, she says, it is very clear that the side effects of smoking, such as cancer, emphysema and heart disease, make that nicotine delivery system far too dangerous. I'm Tom Britt.
McBride says the benefits of nicotine itself can be compared to caffeine.
Cut 2...delivery system...:20 . . . ( Preview this in a WAV file in 16-bit mono. )
"Nicotine has a lot of therapeutic uses. There's growing evidence that it may be useful in treating Parkinson's disease, Alzheimer's - their level of concentration, their ability to focus. Those of us who are caffeine users understand that. Fortunately, coffee hasn't been shown to be a negative or harmful delivery system."
http://www.dukemednews.duke.edu/av/medminute.php?id=2880Here is another
http://www.sciencenews.org/articles/20041106/fob2.aspNicotine's Good Side: Substance curbs sepsis in mice
Diana Parsell
Small doses of nicotine can halt the progression of the often-fatal condition called sepsis, according to experiments in mice. The finding, coupled with tests of nicotine on cultured human cells, suggests a pathway to more-effective therapies for the infection-triggered problem.
Twice as many mice injected with nicotine survived at least 3 weeks after sepsis set in than did mice receiving inert injections. Luis Ulloa of the Institute for Medical Research at North Shore-Long Island Jewish Health System in Manhasset, N.Y., and his coinvestigators conclude that the treatment works by inhibiting overproduction of an immune system molecule that promotes inflammation.
Other studies have suggested that nicotine may be effective against inflammatory diseases such as ulcerative colitis, which is chronic inflammation of the large intestine.
When Ulloa and his colleagues began experimenting in lab dishes with human macrophages, a type of immune system cell, they discovered that the biochemical acetylcholine put the brakes on the cells' production of the protein called high mobility group box 1 (HMBG1). This protein is one of the family of immune chemicals called cytokines, which play a role in infection-fighting inflammation. In sepsis, however, HMBG1 overstimulates inflammation.
snip
Ulloa expects the findings to lead to the development of new, nicotinelike compounds that can reduce inflammatory diseases while avoiding the side effects of nicotine, which include nausea and heart and blood vessel problems. "However, these are preclinical studies, and future studies are needed to evaluate potential effects of human use" of such compounds, he adds.
Effective new therapies for sepsis could have tremendous medical benefits. In the United States, sepsis kills a third of the 750,000 people who experience it each year, accounting for 9 percent of U.S. deaths. Current treatment consists of antibiotics and critical care to prevent organ failure, but sepsis often spreads too rapidly for physicians to halt its damage.
Pathologist Peter A. Ward of the University of Michigan Health System in Ann Arbor says, "There's every reason to think
might ultimately have clinical implications." The goal for treatment of sepsis and other inflammatory conditions, he explains, is to find ways of enlisting the body's natural regulators.